Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-07985631 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Cohort 1: single ascending dose | EXPERIMENTAL | Dose A (3 active: 2 placebo) |
| Cohort 2: single ascending dose | EXPERIMENTAL | Dose B (3 active: 2 placebo) |
| Cohort 3: single ascending dose | EXPERIMENTAL | Dose C (6 active: 2 placebo) |
| Cohort 4: single ascending dose | EXPERIMENTAL | Dose D (6 active: 2 placebo) |
| Cohort 5: single ascending dose | EXPERIMENTAL | Optional Cohort with dose to be determined (6 active: 2 placebo) |
| Cohort 6: single ascending dose | EXPERIMENTAL | Optional Cohort with dose to be determined (6 active: 2 placebo) |
| Cohort 7: single ascending dose | EXPERIMENTAL | Optional Cohort with dose to be determined (6 active: 2 placebo) |
| Cohort 8: single dose | EXPERIMENTAL | Optional Japanese Cohort dose to be determined (4 active: 1 placebo) |
| Cohort 9: single dose | EXPERIMENTAL | Optional Chinese Cohort dose to be determined (4 active: 1 placebo) |
| Cohort 10: multiple dose | EXPERIMENTAL | Optional Cohort with dose to be determined (6 active: 2 placebo) |
| Cohort 11 | EXPERIMENTAL | Optional Cohort with dose to be determined (6 active: 2 placebo) |
| Cohort 12 | EXPERIMENTAL | Optional Cohort with dose to be determined (6 active: 2 placebo) |
| Cohort 13 | EXPERIMENTAL | Optional Cohort with dose to be determined (6 active: 2 placebo) |
| Name | Type | Description |
|---|---|---|
| PF-07985631 | DRUG | Experimental Pfizer compound which will be SC or IV |
| Placebo | DRUG | Placebo which will be SC or IV |
Inclusion: 1. Between 18 and 45 years of age who are overtly healthy. 2. Japanese/Chinese and multiple dose cohorts only: Adult participants 18 to 55 years of age who are overtly healthy may be eligible at the discretion of PI. 3. Japanese/Chinese cohorts only: Participants must have 4 biological J...
PF-07985631 is an investigational small molecule being studied in healthy adults. It is currently in a Phase 1 clinical trial to evaluate how different amounts of the study medicine are tolerated and how it acts in the body. It is not approved for any condition and remains in clinical development.
PF-07985631 is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. The company is conducting a Phase 1 clinical trial of this investigational small molecule in healthy adult volunteers.
PF-07985631 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The ongoing Phase 1 study is recruiting participants to assess the tolerability and pharmacokinetics of different doses in healthy adults.
PF-07985631 is being studied in one active Phase 1 clinical trial with the identifier NCT06994897. This randomized, double-blind, controlled study is recruiting 92 healthy adults in Belgium to evaluate how different amounts of the study medicine are tolerated and act in the body.
PF-07985631 is not FDA approved. It is an investigational small molecule currently in Phase 1 clinical development. The ongoing trial is designed to assess safety, tolerability, and how the drug behaves in the body of healthy adults, which is an early stage of the drug development process.